AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 196.79B +22.6% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 25.23 |
| Forward PE | 15.98 |
| Dividend | 2.36 (1.86%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 157,148 |
| Open | 12,650 |
| Previous Close | 12,688 |
| Day's Range | 12,578 - 12,654 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 15,773.01 (+25.14%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,773p, which is an increase of 25.14% from the latest price.
News
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants diges...
AstraZeneca 'magic' faces rare test after trial failure, share slide
AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and mai...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to con...
AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cancer Treatment
AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cancer Treatment
AstraZeneca announces Etcamah with CDK4/6 inhibitor approved in EU
AstraZeneca’s (AZN) Etcamah in combination with a cyclin-dependent kinase, CDK, 4/6 inhibitor has been approved in the European Union, EU, for the treatment of adult patients with estrogen receptor-po...
AstraZeneca Secures EU Nod For Etcamah In Advanced Breast Cancer
(RTTNews) - AstraZeneca (AZN) on Thursday announced that the company's Etcamah (camizestrant) in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib)...
AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues
The approval opens a big market for camizestrant as U.S. regulators continue to review the company's application there.
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $AZN--AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm.
Hair loss with GLP-1 drugs is rare, but real, studies find
The risk of hair loss in patients taking GLP-1 drugs for obesity or diabetes, while low, is higher than with other diabetes drugs, new studies suggest.
Royalty Pharma buys royalty interest in AstraZeneca cliramitug for $125M upfront
Royalty Pharma (RPRX) announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s (AZN) cliramitug for up to $425M, including $125M upfront. Cliramitug is a Phase 3…
Royalty Pharma Acquires Neurimmune's Royalty Interest In AstraZeneca's Cliramitug For $425 Mln
(RTTNews) - Wednesday, Royalty Pharma plc (RPRX) announced the acquisition of Neurimmune's royalty interest in AstraZeneca's (AZN) cliramitug for up to $425 million.
AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regulations
AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regulations
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to...
Abivax re-engages Centerview amid renewed takeover interest, La Lettre says
Marc de Garidel’s company suspended takeover talks with pharma giants including AstraZeneca (AZN) and Eli Lilly (LLY) last month as it secured an EUR 800M capital raise. Its new funding…
AstraZeneca price target lowered to 15,300 GBp at Morgan Stanley
Morgan Stanley lowered the firm’s price target on AstraZeneca (AZN) to 15,300 GBp from 16,500 GBp and keeps an Overweight rating on the shares.
AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky
AstraZeneca (AZN) shares fell roughly 8% as the market opened on July 9, 2026. Investors who held AZN and lost money are examining whether the losses tied to this collapse may be recoverable.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to con...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to...
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving AstraZeneca (AZN)
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- AstraZeneca plc (NYSE: AZN) shares dropped approximately 8% premarket on July 9, 2026, after the Company announced that the Phase III CARDIO-TTransform tria...
AstraZeneca Secures Licensing Deal for Zegfrovy (AZN)
AstraZeneca Secures Licensing Deal for Zegfrovy (AZN)
AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Cancer Drug Acquisition
AstraZeneca (AZN) Expands Oncology Portfolio with $600M Lung Cancer Drug Acquisition
AstraZeneca to acquire rights to develop, commercialize Zegfrovy for $600M
Dizal announced that it has entered into a global exclusive license agreement with AstraZeneca (AZN) for Zegfrovy, an oral irreversible epidermal growth factor receptor, or EGFR, inhibitor for patient...
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion
AstraZeneca entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment.
AstraZeneca Enters Global License Agreement For Zegfrovy
LONDON (dpa-AFX) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) has entered into an exclusive license agreement with Dizal Pharmaceutical Co., Ltd for Zegfrovy, an oral irreversible epidermal growth f...
AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to one of its drugs for a type of lung cancer, the Chinese drugmaker said in a filing to the Shanghai stock exchange ...